Metastatic Esophageal Squamous Cell Carcinoma
Conditions
Keywords
metastatic esophageal squamous cell carcinoma, anti-PD-1, Capecitabine, chemoradiotherapy
Brief summary
Retrospective studies suggested that the addition of thoracic concurrent chemoradiotherapy to systemic chemotherapy improved the survival and quality of life (QOL) of patients with metastatic esophageal squamous cell carcinoma (ESCC). However, no prospective study had been conducted to confirm these findings. Recently, immunotherapy targeting the PD-1/PD-L1 checkpoints combined with chemotherapy had been proved to significantly prolong the survival of those patients compared with chemotherapy alone. Moreover, anti-PD-1 combined with radiotherapy exerts a synergistic anti-tumor effect, which may further improve the combination efficacy. This randomized, phase II study aimed to evaluate the efficacy and safety of the chemotherapy and anti-PD-1 combined with concurrent chemoradiotherapy to primary tumor versus systemic therapy alone in stage IVB ESCC. Of note, non-regional lymph node metastasis only was the stratification factor in the random assignment.
Interventions
COMBINATION_PRODUCTIntensity-modulated radiotherapy concurrent with capecitabine
All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Eastern Cooperative Oncology Group performance status ≤ 2 2. Histologically confirmed squamous cell carcinoma of the esophagus; 3. Diagnosed with stage IVB disease (according to UICC TNM version 8); 4. Received 4 to 6 cycles of standard chemotherapy (fluoropyrimidine or taxane-based platinum doublet chemotherapy) and anti-PD1 treatment, and no progression disease was confirmed; 5. Estimated life expectancy \>4 months; 6. The function of important organs meet the following requirements: a. white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥ 100×109/L; c. hemoglobin ≥ 9g/dL; d. serum albumin ≥ 2.8g/dL; e. total bilirubin ≤ 1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; f. serum creatinine ≤ 1.5×ULN or creatinine clearance rate \>60 mL/min; 7. Ability to understand the study and sign informed consent.
Exclusion criteria
1. Progression was confirmed after completion of 4 to 6 cycles of standard chemotherapy and anti-PD1 treatment; 2. Patients with intracranial metastasis disease at diagnosis; 3. History of thoracic irradiation; 4. Known or suspected allergy or hypersensitivity to monoclonal antibodies and the chemotherapeutic drugs: Capecitabine, paclitaxel, or platinum; 5. Patients who have a preexisting esophagomediastinal fistula and/or esophagotracheal fistula; 6. A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer 7. Patients who cannot tolerate chemoradiotherapy due to severe cardiac, lung, liver, or kidney dysfunction, or hematopoietic disease or cachexia. 8. Inability to provide informed consent due to psychological, familial, social, and other factors; 9. Female patients who are pregnant or during lactation; 10. Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation; 11. A history of interstitial lung disease or non-infectious pneumonia; 12. Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1-year progression-free survival | From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 12 months | The 1-year progression-free survival of each group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1-year overall survival | From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 12 months | The 1-year overall survival of the each group |
| ORR | 3 months after chemoradiotherapy (plus or minus 14 days) | Overall response rate |
| Treatment-related adverse events | From the start of treatment to 2 year after the completion of treatment | Toxicity of treatment was evaluated according to CTCAE 4.0 |
Countries
China
Contacts
Primary ContactMian Xi, MD
Outcome results
None listed